Spyre Therapeutics, Inc. SYRE Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s common stock, par value (in dollars per share)?
- Spyre Therapeutics, Inc. (SYRE) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
- How has Spyre Therapeutics, Inc.'s common stock, par value (in dollars per share) changed year-over-year?
- Spyre Therapeutics, Inc.'s common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Spyre Therapeutics, Inc.'s common stock, par value (in dollars per share)?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.